补充与替代疗法治疗肠易激综合征的研究进展

肠易激综合征是临床常见的功能性胃肠病之一。由于多数患者的症状经过一线药物治疗后仍不能得到较好改善，许多患者为获得更好的治疗效果，转向选择补充与替代疗法进行治疗。然而，由于研究质量和数量的限制，大部分治疗肠易激综合征的补充与替代疗法并未被相关共识和指南所推荐。本文从补充与替代疗法的分类入手，从天然产品、身心治疗、传统医药3个方面就目前国内外常用的补充与替代疗法治疗肠易激综合征的研究进行概述，以期为临床工作者和患者更好地了解和应用提供帮助。     

肠易激综合征辨证分析

肠易激综合征（IBS）是一组持续存在或反复发作的临床症候群,主要症状有腹痛、腹胀、排便习惯改变和大便性状异常、黏液便等,经检查排除可引起这些症状的器质性疾病。临床分为肝木乘脾型腹泻、脾胃虚弱型腹泻、脾肾阳虚型腹泻、肝郁脾虚型便秘四型,根据临床辨证分别施以不同治法,不同方药治疗,有显著疗效。同时,教育患者平时养成良好的饮食卫生习惯,不饮生水,不食生冷瓜果,忌食辛辣、油腻、肥厚之品,保持心情舒畅,怡情悦志,注意保暖,可加强疗效,防止复发。     

腹泻型、便秘型肠易激综合征和功能性便秘患者的直肠肛管测压比较

目的研究腹泻型、便秘型IBS和功能性便秘患者直肠肛管测压参数的不同，并评价性别和年龄对各项参数的影响，方法腹泻型IBS(n=18)、便秘型IBS(n=14)、功能性便秘(n=30)和健康对照组(n=18)，通过定点牵拉法进行直肠肛管测压。结果腹泻型IBS、便秘型IBS、功能性便秘以及健康对照组直肠肛管测压各项压力参数基本无差异，但三组患者的诱发RAIR所需的最小气体容量均显著高于健康对照组，便秘型IBS和功能性便秘模拟排便时发生矛盾运动的百分比显著高于腹泻型IBS和健康对照组；便秘型IBS和功能性便秘组中，肛管上部和下部最大紧缩压力，以及模拟排便发生矛盾运动的百分比男性均高于女性；腹泻型IBS组内男性模拟排便发生矛盾运动的百分比高于女性；健康对照组内男性肛管下部静息压力和最大紧缩压力高于女性；各组20-50岁人群和50-80岁人群的各项压力参数无显著性差异，但功能性便秘组青年组诱发RAIR所需的最小气体容量低于老年组。结论腹泻型IBS、便秘型IBS和功能性便秘患者的直肠肛管测压各项压力参数无助于这三型功能性肠病的鉴别诊断。男性的直肠肛管测压的多项压力参数显著高于女性，男性更易出现模拟排便矛盾运动，年龄对直肠肛管测压各项参数无明显影响。     

Factor analysis of bowel symptoms in US and Italian populations

BACKGROUND AND AIMS: Functional gastrointestinal disorders are diagnosed by the presence of a characteristic set of symptoms. Aims of this study were to validate the Rome symptom criteria by factor analysis and to determine whether symptoms cluster in the same way in different cultures. METHODS: One thousand forty-one gastroenterology clinic patients in the US (response rate 53%) and 228 family members accompanying clinic patients in Italy (84%) completed a previously validated symptom questionnaire. Factor analysis identified clusters of symptoms which are highly correlated with each other, and these were compared to the Rome diagnostic criteria. RESULTS: In the US, 13 factors were identified. The irritable bowel factor was composed of three core symptoms corresponding to the Rome II classification system. Two dyspepsia factors were identified which correspond to the ulcer- and motility-like subtypes proposed in the Rome I classification system. All symptoms of constipation formed a single cluster as proposed in the Rome II classification system. Symptom clusters in the US agreed well with symptom clusters identified in Italian subjects. CONCLUSIONS: Empirically derived symptom clusters agree in most respects with the Rome II classification system and support their validity. These symptom clusters are independent of cultural differences in diet and behaviour.     

Irritable bowel syndrome: The role of psychosocial factors

The irritable bowel syndrome (IBS) is a very common disorder of intestinal function characterized by variable symptoms of abdominal pain, diarrhea, constipation and bloating. The spectrum of severity ranges from mild symptoms, not worthy of clinical attention, to intense and continuous symptoms associated with impaired health-related quality of life and high health care use. Psychosocial disturbance is commonly found among patients with irritable bowel, but until recently, its precise role in the disorder was uncertain. The data now suggest that irritable bowel is not a psychiatric disorder per se, but psychosocial factors including life stress, psychiatric comorbidity and abnormal illness behavior, among others, influence how the illness is experienced and acted upon. Patients with mild symptoms usually respond to education, reassurance, dietary modification and, when needed, antimotility agents. However, patients with more severe symptoms, who usually have greater psychosocial disturbance, will also require behavioral interventions, and possibly psychopharmacological agents. In sum, a graduated, multicomponent plan of care that includes dietary, behavioral and pharmacological treatments is recommended.     

盐酸帕罗西汀治疗肠易激综合征伴焦虑抑郁的疗效观察

目的研究盐酸帕罗西汀对肠易激综合征（IBS）伴焦虑抑郁的临床疗效。方法Zung氏抑郁量袁（SDS）≥40分者；Hamilton焦虑量表（HAMA）〉14分者，服用帕罗西汀10～30mg tid（失眠烦躁明显者每晚临时服用苯二氮卓类药物1周）治疗，6周后用SDS及HAMA的减分率评定疗效。以减分率〉25％且躯体症状有改善为有效。结果86例患者中焦虑抑郁障碍改善达84％以上，躯体症状改善达540以上。结论帕罗西汀可有效改善肠易激综合征伴有的焦虑抑郁及躯体性不适症状。     

Diarrhea Predominant-Irritable Bowel Syndrome (IBS-D): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms

Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by abdominal pain associated with defecation or a change in bowel habits. Gut microbiota, which acts as a real organ with well-defined functions, is in a mutualistic relationship with the host, harvesting additional energy and nutrients from the diet and protecting the host from pathogens; specific alterations in its composition seem to play a crucial role in IBS pathophysiology. It is well known that diet can significantly modulate the intestinal microbiota profile but it is less known how different nutritional approach effective in IBS patients, such as the low-FODMAP diet, could be responsible of intestinal microbiota changes, thus influencing the presence of gastrointestinal (GI) symptoms. The aim of this review was to explore the effects of different nutritional protocols (e.g., traditional nutritional advice, low-FODMAP diet, gluten-free diet, etc.) on IBS-D symptoms and on intestinal microbiota variations in both IBS-D patients and healthy subjects. To date, an ideal nutritional protocol does not exist for IBS-D patients but it seems crucial to consider the effect of the different nutritional approaches on the intestinal microbiota composition to better define an efficient strategy to manage this functional disorder.     

国产万拉法新治疗肠易激综合征的初步临床研究

目的 观察国产新药万拉法新对肠易激综合征（IBS）及其伴随的焦虑和抑郁症状的临床治疗效果。方法 选择48例IBS患者,随机分为治疗组和对照组,分别服用万拉法新及硝苯地平进行为期4周的治疗,通过对IBS各项症状的改善率和总体改善率评定观察治疗效果。同时采用Zung编制的抑郁自评量表和焦虑自评量表进行评分观察治疗前后抑郁和焦虑的改善程度。结果 万拉法新对IBS的治疗总体改善率为80％,对照组为52．17％（P＜0．05）。万拉法新治疗前后焦虑和抑郁的改善程度经检验均有统计学意义（P＜0．01）。结论 单独应用万拉法新对IBS的总体治疗效果优于硝苯地平组,对改善伴随的焦虑和抑郁症状有明显的疗效。